Literature DB >> 31493966

Toxicity From Unintentional Pediatric Ingestion of a Performance-Enhancing Drug: A Case Report With Review of Clenbuterol Toxicity and Treatment.

Caitlin F Bonney1, Benjamin Hatten2, George S Wang3.   

Abstract

BACKGROUND: Clenbuterol is a long-acting β-adrenergic agonist that is not Food and Drug Administration-approved for use in the United States, but may be obtained without a prescription from various unregulated sellers. It has seen increasing use as a performance-enhancing drug for sports. Literature on pediatric toxicity and treatment is limited. CASE REPORT: We report a case of a 2-year-old female presenting after an exploratory ingestion of clenbuterol. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Use of performance-enhancing agents is increasing and physicians should be aware of the potential toxicity of intentional and unintentional ingestions of β-adrenergic agonists. Patients may exhibit nausea, vomiting, tremor, tachycardia, and hypotension, along with laboratory abnormalities, including hyperglycemia, hypophosphatemia, hypokalemia, and hyperglycemia. Hypotension might not respond to adrenergic agents and may require administration of β-adrenergic antagonists to maintain adequate perfusion.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  clenbuterol; performance-enhancing drugs; β-adrenergic agonist

Mesh:

Substances:

Year:  2019        PMID: 31493966     DOI: 10.1016/j.jemermed.2019.06.016

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  2 in total

1.  Clenbuterol: a new toxic substance in paediatrics.

Authors:  Andrew A Tester; Sheena Logan; Louisa Pollock; Allison McKie
Journal:  BMJ Case Rep       Date:  2020-03-12

2.  Detection of clenbuterol residues in beef sausages and its enantiomeric analysis using UHPLC-MS/MS: A risk of unintentional doping in sport field.

Authors:  Benjamín Velasco-Bejarano; Ricardo Velasco-Carrillo; Evangelina Camacho-Frias; Jahir Bautista; Raquel López-Arellano; Leonardo Rodríguez
Journal:  Drug Test Anal       Date:  2022-02-15       Impact factor: 3.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.